In the present study we have targeted MMP-2 and MMP-9 overactivation in diabetic neuropathy using a known MMP-2 and MMP-9 inhibitor, minocycline with a non-selective COX inhibitor aspirin. Here, MMP9 is linked to diabetic neuropathy.